Product
GR1801
1 clinical trial
1 indication
Indication
Rabies Post-exposure ProphylaxisClinical trial
A Phase III Clinical Trail to Evaluate the Efficacy,Safety,Pharmacokinetics and Immunogenicity Characteristics of GR1801 Injection for the Post-exposure Prophylaxis (PEP) of WHO Category 3 Rabies Exposure Patients.Status: Recruiting, Estimated PCD: 2023-09-06